Proud of @paslombardi for his efforts in addressing unmet needs in 2L therapy for HCC

If you are at #ESMO25 have a look at our posters about #QoL and #PROs: 3152P by Delia Bellino about compliance with #QoL questionnaires in cancer clinical trials; 3153P by Giorgia Intilisano about #QoL results of new cancer drugs recently approved by European Medicines Agency

LEVIATHAN demonstrates not all TKIs are equally effective after Atezolizumab + Bevacizumab in #HCC - new 2L benchmarks thanks to @paslombardi at @ImperialSandC https://t.co/LxZMAEF16v

Quality of life matters in #HCC! Read our last network meta-analysis now online on @JAMAOnc @DJPinato @cabibbo78 @A_DAlessioMD @FulgenziClaudia @BeStef33 @gfmanfredi @paslombardi

The best team I could ever dream of! Two of the best posters in this photo (at my sides) 🙄 #ESMOGI @myESMO @DJPinato @paslombardi @imperialcollege

Best Poster Prize for “Hepatocellular and Non-Biliary Liver Cancer” at @myESMO #ESMOGI25 🏆Awarded to @paslombardi 👉Clinical refractoriness to AtezoBev in HCC Congratulations, very well defended piece of work 👏🏻👏🏻 #ESMOAmbassadors

Have a look at our poster, board 228, about therapeutic decisions and outcome of patients with stage I testicular germ cell tumor. A setting where overtreatment is an issue and communication with pts is crucial. #ASCO25 #isabellacavaglià #ilariadepetris @unito @cittasalute_to

#ESMO24 | Bishal Gyawali: “Let’s try to bring common sense back into oncology”. @oncology_bg @myESMO @fperrone62 @MassimoDiMaio75 @darioT_ @lucadf @forwardRPM

LESS CODE, MORE RESULTS! 💪 Nonlinearity with Numeric Predictors in Logistic Regression Solved! Watch the video for more details: https://t.co/G0IapXBiec #rstats #statistics #dataanalysis #stats #datascience #r4ds #dataanalytics

Precision Targeting of the Gut Microbiome for Cancer Immunotherapy: amongst failures and challenges we need a moment of reflection @paslombardi @ImperialSandC - delighted for the opportunity to put our thoughts together offered by @CD_AACR https://t.co/kFDYwh0lDr

Ecstatic and proud to share the NICHE-2 results, now published in @NEJM. Out of 111 pts, 95% had an MPR , and 68% a pCR after only 4 weeks of #neoadjuvant #immunotherapy. Grateful to the pts and colleagues who made this possible. @HaanenJohn https://t.co/h7xgmjOfjz

Efficacy of etrumadenant (increases Adenosin) & zimberelimab (anti-PD) vs Regorafenib in previously treated mCRC 🔎 ARC-9 phs-2, 112 pts 👉ORR 17 vs 2% 👉mPFS 6.2 vs 2.1 mo, HR 027 👉mOS 19.7 vs 9.5 mo 🧐Longest OS in 3rd line so far reported, meaningful improvements @myESMO

One of the brightest minds 🔥 in Cancer Research @FulgenziClaudia came tip toeing to London a few years back. I knew she was clever 🧚‍♂️ and the world now knows too 🌎 @ImperialSandC @ImperialAHSC @ImperialBRC thanks to @profbower and @thenasheffect for mentorship and support 🥇

Tonight we say goodbye to @BeStef33 from @Unibo who so much has done at @ImperialSandC to improve our knowledge and practice of #immunotherapy in #HCC - best of luck 🤞 🔥 @ImperialAHSC

Delighted to have hosted our first @imperialcollege HCC Masterclass with an outstanding faculty @BeStef33 @A_DAlessioMD @LorenzaRimassa @BargelliniIrene @CiroCelsa @FulgenziClaudia @paslombardi at @ImperialSandC

Today meet Gaia who is studying complex genomic profile of high-grade serous carcinomas. Her aim is to understand which alterations in cancer cells cause their clinical behaviour and their response and resistance to new targeted drugs for a more personalized approach for patients

Immunotherapy is truly changing all stages of hepatocellular carcinoma⁦. Honoured to have been tasked to make sense of this change with ⁦@A_DAlessioMD⁩ ⁦@FulgenziClaudia⁩ for ⁦@NatureMedicine⁩ ⁦@ImperialSandC⁩ ⁦@UniAvogadro⁩

Cinque manganellate in dieci giorni: 13 febbraio, davanti alla sede Rai di Napoli 13 febbraio, davanti alla sede Rai di Torino 15 febbraio, davanti alla sede Rai di Bologna 23 febbraio, in centro a #Pisa 23 febbraio, in centro a Firenze

I’m appalled to learn that in the middle of a war, the Israeli gov is poised to commit new funds to build more illegal settlements. This is not self-defence and will not make Israel safer. The settlements are grave IHL breach, and they are Israel’s greatest security liability.

In a phase 2 trial, the oral type II RAF inhibitor #tovorafenib exhibited an overall response rate of 67% in patients with BRAF-altered relapsed/refractory pediatric low-grade #glioma @ChildrensNatl @DayOneBio @drsam #btsm #SNO2023